About Us

Teikoku Pharma USA located in San Jose California and headquartered in Kagawa Japan, is a pharmaceutical company focused on the research and development of treatments for CNS, Pain Management and Oncology.  Founded in 1997, the company successfully developed Lidocaine 5% patch worldwide under Lidoderm®, Lidotop® and  Versatis® brands.  To date, 2 billion Lidocaine 5% patches have been distributed in 59 countries.  TPU recently also received NDA approval for Non-alcohol Docetaxel injection currently available in the US.

Latest News and Events

September 6, 2016

SAN JOSE, Calif., September 6, 2016 -- Teikoku Pharma USA Inc. ("TPU") today announced that it has entered into an exclusive license agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (“Luoxin”) to market, sell and distribute TPU's Docetaxel Injection, Non-Alcohol Formula in China.

Read more | View All


Teikoku is building a robust pipeline of drug candidates which may expand the reach and benefit of existing therapeutics.   

Learn more about our pipeline.


Teikoku USA has two FDA and one EMEA approved products in the market.
Learn more about our approved products.


We employ our Hydrohesive, Matrix and other drug delivery technologies to expand our product pipeline.
Learn More About Our Technologies.